拉尼蘭諾
化合物
拉尼蘭諾是一種泛PPAR激動劑，是第一種同時針對PPAR-α、PPAR-β和PPAR-γ的靶向藥物。[1][2][3]截至2023年，正在進行非酒精性脂肪性肝炎的III期試驗；與針對相同病症進行III期試驗的其他藥物相比，其優勢在於它對脂肪性肝炎和纖維化都有改善作用。[4]
 | |
| 識別資訊 | |
|---|---|
| |
| CAS號 | 927961-18-0 |
| PubChem CID | |
| UNII | |
| ECHA InfoCard | 100.218.645 |
| 化學資訊 | |
| 化學式 | C19H15ClN2O4S2 |
| 摩爾質量 | 434.91 g·mol−1 |
參考文獻
編輯- ^ Derrett-Smith, Emma; Clark, Kristina E. N.; Shiwen, Xu; Abraham, David J.; Hoyles, Rachel K.; Lacombe, Olivier; Broqua, Pierre; Junien, Jean Louis; Konstantinova, Irena; Ong, Voon H.; Denton, Christopher P. The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis. Arthritis Research & Therapy. 6 September 2021, 23 (1): 234 [2023-11-23]. ISSN 1478-6362. doi:10.1186/s13075-021-02592-x
. （原始內容存檔於2023-11-23）.
- ^ Boyer-Diaz, Zoe; Aristu-Zabalza, Peio; Andrés-Rozas, María; Robert, Claude; Ortega-Ribera, Martí; Fernández-Iglesias, Anabel; Broqua, Pierre; Junien, Jean-Louis; Wettstein, Guillaume; Bosch, Jaime; Gracia-Sancho, Jordi. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. Journal of Hepatology. May 2021, 74 (5): 1188–1199. doi:10.1016/j.jhep.2020.11.045 .
- ^ Francque, Sven M.; Bedossa, Pierre; Ratziu, Vlad; Anstee, Quentin M.; Bugianesi, Elisabetta; Sanyal, Arun J.; Loomba, Rohit; Harrison, Stephen A.; Balabanska, Rozalina; Mateva, Lyudmila; Lanthier, Nicolas; Alkhouri, Naim; Moreno, Christophe; Schattenberg, Jörn M.; Stefanova-Petrova, Diana; Vonghia, Luisa; Rouzier, Régine; Guillaume, Maeva; Hodge, Alexander; Romero-Gómez, Manuel; Huot-Marchand, Philippe; Baudin, Martine; Richard, Marie-Paule; Abitbol, Jean-Louis; Broqua, Pierre; Junien, Jean-Louis; Abdelmalek, Manal F. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. New England Journal of Medicine. 21 October 2021, 385 (17): 1547–1558 [2023-11-23]. ISSN 0028-4793. doi:10.1056/NEJMoa2036205 . （原始內容存檔於2023-11-23） （英語）.
- ^ Harrison, Stephen A.; Loomba, Rohit; Dubourg, Julie; Ratziu, Vlad; Noureddin, Mazen. Clinical Trial Landscape in NASH. Clinical Gastroenterology and Hepatology. July 2023, 21 (8): 2001–2014. doi:10.1016/j.cgh.2023.03.041.
